# Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants

> **NCT06190691** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 36 (actual)

## Conditions studied

- Healthy
- Hepatic Insufficiency

## Interventions

- **DRUG:** Pirtobrutinib

## Key facts

- **NCT ID:** NCT06190691
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-18
- **Primary completion:** 2021-12-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06190691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06190691, "Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06190691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*